Trial Profile
Randomized, Open Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-Cell Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Sargramostim (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms PREMIER
- Sponsors Bayer; Berlex Inc
- 13 Apr 2010 'Genzyme Corporation' added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
- 13 Apr 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 30 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.